Tepoxalin (CAS 103475-41-8)
CAS Number:
103475-41-8
Molecular Weight:
385.84
Molecular Formula:
C20H20ClN3O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Tepoxalin is a compound that acts as a dual inhibitor, targeting both COX and 5-lipoxygenase (5-LO) enzymes. Additionally, it selectively inhibits the activity of 12-lipoxygenase (12-LO) while not affecting 15-lipoxygenase (15-LO). By exerting its inhibitory effects, tepoxalin effectively decreases the production of thromboxane B2 (TXB2) and leukotriene B4 (LTB4) in human peripheral blood mononuclear cells (PBMCs) stimulated by the calcium ionophore A23187. Furthermore, it displays the ability to mitigate epinephrine-induced platelet aggregation in human platelet-rich plasma (PRP).
Tepoxalin (CAS 103475-41-8) References
- Tepoxalin inhibits inflammation and microvascular dysfunction induced by abdominal irradiation in rats. | Panés, J., et al. 2000. Aliment Pharmacol Ther. 14: 841-50. PMID: 10848671
- Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor. | Fusellier, M., et al. 2005. J Vet Pharmacol Ther. 28: 581-6. PMID: 16343292
- An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model. | Macrory, L., et al. 2009. BMC Vet Res. 5: 25. PMID: 19624842
- Oral administration of tepoxalin in the horse: a PK/PD study. | Giorgi, M., et al. 2011. Vet J. 190: 143-9. PMID: 21036634
- Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft. | Sottnik, JL., et al. 2011. Vet Comp Oncol. 9: 118-30. PMID: 21569197
- Pro-apoptotic effects of tepoxalin, a cyclooxygenase/lipoxygenase dual inhibitor, on canine synovial fibroblasts. | Sunaga, T., et al. 2012. J Vet Med Sci. 74: 745-50. PMID: 22240988
- The 5-lipoxygenase inhibitor tepoxalin induces oxidative damage and altered PTEN status prior to apoptosis in canine osteosarcoma cell lines. | Loftus, JP., et al. 2016. Vet Comp Oncol. 14: e17-30. PMID: 24813477
- Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. | Corsello, SM., et al. 2020. Nat Cancer. 1: 235-248. PMID: 32613204
- Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1. | McQuerry, JA., et al. 2021. Transl Oncol. 14: 101181. PMID: 34298440
- Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities. | Tam, SS., et al. 1995. J Biol Chem. 270: 13948-55. PMID: 7775455
- Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression. | Zhou, L., et al. 1996. Eur J Immunol. 26: 120-9. PMID: 8566054
- Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. | Ritchie, DM., et al. 1995. Int J Immunopharmacol. 17: 805-12. PMID: 8707445
- The NF-kappa B inhibitor, tepoxalin, suppresses surface expression of the cell adhesion molecules CD62E, CD11b/CD18 and CD106. | Lee, DH., et al. 1996. Immunol Lett. 53: 109-13. PMID: 9024987
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tepoxalin, 10 mg | sc-473190 | 10 mg | $445.00 |